R
Richard J. Robbins
Researcher at Houston Methodist Hospital
Publications - Â 87
Citations - Â 6142
Richard J. Robbins is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Thyroid cancer & Thyroid carcinoma. The author has an hindex of 36, co-authored 84 publications receiving 5902 citations. Previous affiliations of Richard J. Robbins include Memorial Sloan Kettering Cancer Center & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
Ernest L. Mazzaferri,Richard J. Robbins,Carole A. Spencer,Lewis E. Braverman,Furio Pacini,Leonard Wartofsky,Bryan R. Haugen,Steven I. Sherman,David S. Cooper,Glenn D. Braunstein,Stephanie L. Lee,Terry F. Davies,Baha'uddin M. Arafah,Paul W. Ladenson,Aldo Pinchera +14 more
TL;DR: A surveillance guideline is proposed using TSH-stimulated Tg levels for patients who have undergone total or near-total thyroidectomy and (131)I ablation for DTC and have no clinical evidence of residual tumor with a serum Tg below 1 micro g/liter during THST.
Journal ArticleDOI
Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
Richard J. Robbins,Qiang Wan,Ravinder K. Grewal,Roland Reibke,Mithat Gonen,H. William Strauss,R. Michael Tuttle,William D. Drucker,Steven M. Larson +8 more
TL;DR: FDG-PET scanning is a simple, expensive, but powerful means to restage thyroid cancer patients who develop subsequent metastases, assigning them to groups that are either at low ( FDG negative) or high (FDG positive) risk of cancer-associated mortality.
Journal ArticleDOI
Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas: Results of a Prospective Multicenter Study*
Mark E. Molitch,R. L. Elton,Richard E. Blackwell,B. Caldwell,R. J. Chang,Robert B. Jaffe,G. Joplin,Richard J. Robbins,J. E. Tyson,Michael O. Thorner +9 more
TL;DR: In 19 patients, reduction in tumor size was evident by 6 weeks, but in the other 8, such reduction was not noted until the 6 month evaluation, and a reduction in PRL levels always preceded any detectable change intumor size.
Journal ArticleDOI
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
Weiping Wang,Steven M. Larson,Melissa Fazzari,Satish K. Tickoo,Katherine S. Kolbert,George Sgouros,Henry Yeung,Homer A. Macapinlac,Juan Rosai,Richard J. Robbins +9 more
TL;DR: FDG-PET scanning is incorporated into the routine follow-up of a cohort of thyroid cancer patients undergoing annual evaluations to identify high and low risk subsets and found the single strongest predictor of survival was the volume of FDG-avid disease.
Journal ArticleDOI
[18F]-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels
Weiping Wang,Homer A. Macapinlac,Steven M. Larson,Samuel D.J. Yeh,Tim Akhurst,Ronald D. Finn,Juan Rosai,Richard J. Robbins +7 more
TL;DR: FDG-PET is able to localize residual thyroid cancer lesions in patients who have negative diagnostic 131I whole body scans and elevated Tg levels, although it was not sensitive enough to detect minimal residual disease in cervical nodes.